Deep Track Capital, LP
13F Reported Value
ⓘ$6.9B
incl. option notional
Equity Holdings
ⓘ$6.8B
Option Notional
ⓘ$82.4M
$0 puts / $82.4M calls
Holdings
67
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Deep Track Capital, LP disclosed 67 positions worth $6.9B in its Form 13F-HR for Q2 2026 — $6.8B in common stock plus $82.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $GH (Guardant Health, Inc.) at 7.5% of the equity portfolio, followed by $IMVT and $GPCR. During the quarter the fund opened 19 new positions and exited 15 — including a new stake in $ALNY. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Deep Track Capital, LP’s Form 13F-HR filing with the SEC under CIK 1856083.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 39.0#2,164
Quality
$509.1M3,393,312 sh - —
Quality
$359.9M9,341,151 sh - —
Quality
$254.4M4,740,072 sh - —
Quality
$250.0M4,300,000 sh - 71.4
Quality
$248.3M825,000 sh - —
Quality
$245.9M2,000,000 sh - 55.0
Quality
$230.8M3,666,768 sh - —
Quality
$220.2M1,783,322 sh - —
Quality
$209.6M4,000,000 sh - 8.4
Quality
$193.3M19,686,282 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Guardant Health, Inc.$GH | 39.0#2,164 | $509.1M | 3,393,312 |
 Immunovant, Inc.$IMVT | — | $359.9M | 9,341,151 |
 Structure Therapeutics Inc.$GPCR | — | $254.4M | 4,740,072 |
 Vaxcyte, Inc.$PCVX | — | $250.0M | 4,300,000 |
 ALNYLAM PHARMACEUTICALS, INC.$ALNY | 71.4 | $248.3M | 825,000 |
 Veradermics, Inc$MANE | — | $245.9M | 2,000,000 |
 Tarsus Pharmaceuticals, Inc.$TARS | 55.0 | $230.8M | 3,666,768 |
 Nuvalent, Inc.$NUVL | — | $220.2M | 1,783,322 |
 Alkermes plc.$ALKS | — | $209.6M | 4,000,000 |
 OCULAR THERAPEUTIX, INC$OCUL | 8.4 | $193.3M | 19,686,282 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Deep Track Capital, LP's 67 positions.
Showing top 10 of 67 holdings.
Sector Allocation
Healthcare
$6.8B
Full Holdings — Deep Track Capital, LP (Q2 2026)
All 67 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $GH | Guardant Health, Inc. | $509.1M | 7.5% | +2% | 39 |
| 2 | $IMVT | Immunovant, Inc. | $359.9M | 5.3% | -19% | — |
| 3 | $GPCR | Structure Therapeutics Inc. | $254.4M | 3.8% | +11% | — |
| 4 | $PCVX | Vaxcyte, Inc. | $250.0M | 3.7% | +0% | — |
| 5 | $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $248.3M | 3.7% | NEW | 71.4 |
| 6 | $MANE | Veradermics, Inc | $245.9M | 3.6% | +300% | — |
| 7 | $TARS | Tarsus Pharmaceuticals, Inc. | $230.8M | 3.4% | +2% | 55 |
| 8 | $NUVL | Nuvalent, Inc. | $220.2M | 3.2% | +30% | — |
| 9 | $ALKS | Alkermes plc. | $209.6M | 3.1% | +11% | — |
| 10 | $OCUL | OCULAR THERAPEUTIX, INC | $193.3M | 2.9% | +0% | 8.4 |
| 11 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $189.3M | 2.8% | +188% | 58.2 |
| 12 |  $NRIX | Nurix Therapeutics, Inc. | $187.7M | 2.8% | +22% | 6.4 |
| 13 |  $ORKA | Oruka Therapeutics, Inc. | $183.3M | 2.7% | -5% | — |
| 14 |  $ALMS | ALUMIS INC. | $178.6M | 2.6% | -6% | 7.1 |
| 15 |  $IONS | IONIS PHARMACEUTICALS INC | $174.4M | 2.6% | +13% | 23.4 |
| 16 |  $CMPS | COMPASS Pathways plc | $172.1M | 2.5% | +0% | — |
| 17 |  $VERA | Vera Therapeutics, Inc. | $171.6M | 2.5% | -3% | — |
| 18 |  $AXSM | Axsome Therapeutics, Inc. | $171.3M | 2.5% | -36% | 40.8 |
| 19 |  $GMAB | GENMAB A/S | $155.2M | 2.3% | +54% | 77.9 |
| 20 |  $MLTX | MoonLake Immunotherapeutics | $136.3M | 2.0% | +9% | — |
| 21 |  $COAG | Hemab Therapeutics Holdings, Inc. | $132.3M | 1.9% | NEW | — |
| 22 |  $TNGX | Tango Therapeutics, Inc. | $131.3M | 1.9% | +53% | 17.6 |
| 23 |  $DFTX | Definium Therapeutics, Inc. | $129.4M | 1.9% | -8% | — |
| 24 |  $GRAL | GRAIL, Inc. | $125.3M | 1.9% | +7% | 31.6 |
| 25 |  $BCAX | Bicara Therapeutics Inc. | $121.7M | 1.8% | +1% | — |
| 26 |  $MAZE | Maze Therapeutics, Inc. | $111.4M | 1.6% | +7% | 10.3 |
| 27 |  $CLDX | Celldex Therapeutics, Inc. | $109.4M | 1.6% | +129% | 8.4 |
| 28 |  $LBRX | LB PHARMACEUTICALS INC | $108.8M | 1.6% | +0% | — |
| 29 |  $MBX | MBX Biosciences, Inc. | $95.6M | 1.4% | -37% | — |
| 30 |  $GHRS | GH Research PLC | $89.6M | 1.3% | NEW | — |
| 31 | $GMABCALL | GENMAB A/S | $82.4M | — | NEW | 77.9 |
| 32 |  $COGT | Cogent Biosciences, Inc. | $77.4M | 1.1% | +100% | — |
| 33 |  $ATAI.R1840904 | Atai Beckley N.V. | $76.0M | 1.1% | +20% | — |
| 34 |  $UTHR | UNITED THERAPEUTICS Corp | $67.0M | 1.0% | NEW | 71.3 |
| 35 |  $AVTX | Avalo Therapeutics, Inc. | $66.7M | 1.0% | NEW | 11.7 |
| 36 |  $VRDN | Viridian Therapeutics, Inc.\DE | $66.0M | 1.0% | +158% | 27.2 |
| 37 |  $CYTK | CYTOKINETICS INC | $59.6M | 0.9% | -49% | 28.1 |
| 38 |  $ALT | Altimmune, Inc. | $58.5M | 0.9% | NEW | 8 |
| 39 |  $PSNL | Personalis, Inc. | $53.6M | 0.8% | +33% | 11.3 |
| 40 |  $ACRS | Aclaris Therapeutics, Inc. | $49.4M | 0.7% | +0% | 12 |
| 41 |  $CRMD | CorMedix Inc. | $49.3M | 0.7% | +0% | 78.6 |
| 42 |  $WGS | GeneDx Holdings Corp. | $48.1M | 0.7% | NEW | 35.4 |
| 43 |  $HROW | HARROW, INC. | $41.2M | 0.6% | NEW | 40.5 |
| 44 |  $CRVS | Corvus Pharmaceuticals, Inc. | $37.2M | 0.6% | +0% | — |
| 45 |  $SLDB | Solid Biosciences Inc. | $35.6M | 0.5% | +0% | — |
| 46 |  $BEAM | Beam Therapeutics Inc. | $34.3M | 0.5% | +22% | 34.2 |
| 47 |  $DYN | Dyne Therapeutics, Inc. | $33.3M | 0.5% | -25% | — |
| 48 |  $IMMX | Immix Biopharma, Inc. | $28.6M | 0.4% | NEW | — |
| 49 |  $XFOR | X4 Pharmaceuticals, Inc | $27.5M | 0.4% | -7% | 28 |
| 50 |  $STTK | Shattuck Labs, Inc. | $25.7M | 0.4% | NEW | — |
| 51 |  $MNKD | MANNKIND CORP | $25.6M | 0.4% | NEW | 37.2 |
| 52 |  $IPSC | Century Therapeutics, Inc. | $23.2M | 0.3% | -0% | 33.5 |
| 53 |  $GENB | Generate Biomedicines, Inc. | $22.5M | 0.3% | NEW | — |
| 54 |  $VSTM | Verastem, Inc. | $21.9M | 0.3% | +0% | 29.7 |
| 55 |  $KURA | Kura Oncology, Inc. | $21.7M | 0.3% | -25% | 27.6 |
| 56 |  $ENTA | ENANTA PHARMACEUTICALS INC | $21.1M | 0.3% | -26% | 17.8 |
| 57 |  $NKTR | NEKTAR THERAPEUTICS | $20.9M | 0.3% | NEW | 9.7 |
| 58 |  $OLMA | Olema Pharmaceuticals, Inc. | $18.8M | 0.3% | NEW | — |
| 59 |  $KLRA | Kailera Therapeutics, Inc. | $15.4M | 0.2% | NEW | — |
| 60 |  $KARD | Kardigan, Inc. | $14.3M | 0.2% | NEW | — |
| 61 |  $ELVN | Enliven Therapeutics, Inc. | $11.4M | 0.2% | NEW | — |
| 62 |  $PMN | ProMIS Neurosciences Inc. | $11.0M | 0.2% | +0% | — |
| 63 |  $IMCR | Immunocore Holdings plc | $9.9M | 0.1% | -84% | — |
| 64 |  $XNCR | Xencor Inc | $9.6M | 0.1% | NEW | 11.6 |
| 65 |  $CNTX | Context Therapeutics Inc. | $4.1M | 0.1% | +0% | — |
| 66 |  $IVA | Inventiva S.A. | $3.0M | 0.0% | -35% | — |
| 67 |  $ALGS | Aligos Therapeutics, Inc. | $2.6M | 0.0% | +0% | — |
New Positions (19)
$ALNY ALNYLAM PHARMACEUTICALS, INC.$248.3M$COAG Hemab Therapeutics Holdings, Inc.$132.3M$GHRS GH Research PLC$89.6M$GMABCALL GENMAB A/S$82.4M$UTHR UNITED THERAPEUTICS Corp$67.0M$AVTX Avalo Therapeutics, Inc.$66.7M$ALT Altimmune, Inc.$58.5M$WGS GeneDx Holdings Corp.$48.1M$HROW HARROW, INC.$41.2M$IMMX Immix Biopharma, Inc.$28.6M$STTK Shattuck Labs, Inc.$25.7M$MNKD MANNKIND CORP$25.6M$GENB Generate Biomedicines, Inc.$22.5M$NKTR NEKTAR THERAPEUTICS$20.9M$OLMA Olema Pharmaceuticals, Inc.$18.8MExited Positions (15)
$APLS Apellis Pharmaceuticals, Inc.
$CNTA Centessa Pharmaceuticals plc
$BBIO BridgeBio Pharma, Inc.
$TERN Terns Pharmaceuticals, Inc.
$GERN GERON CORP
$ANIP ANI PHARMACEUTICALS INC
$SLNO SOLENO THERAPEUTICS INC
$ENGN enGene Therapeutics Inc.
$APGE Apogee Therapeutics, Inc.
$JANX Janux Therapeutics, Inc.
$CBIO CRESCENT BIOPHARMA, INC.
$LRMR Larimar Therapeutics, Inc.
$HELP CYBIN INC.
$BLLN BillionToOne, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Deep Track Capital, LP including:
Track Deep Track Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Deep Track Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Deep Track Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Deep Track Capital, LP (SEC CIK: 1856083), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Deep Track Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.